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Abstract
Background: Lymphopenia results in the proliferation and differentiation of naı ¨ve T cells into memory-like cells in the
apparent absence of antigenic stimulation. This response, at least in part due to a greater availability of cytokines, is thought
to promote anti-self responses. Although potentially autoreactive memory-like CD8
+ T cells generated in a lymphopenic
environment are subject to the mechanisms of peripheral tolerance, they can induce autoimmunity in the presence of
antigen-specific memory-like CD4
+ T helper cells.
Methodology/Principal Findings: Here, we studied the mechanisms underlying CD4 help under lymphopenic conditions in
transgenic mice expressing a model antigen in the beta cells of the pancreas. Surprisingly, we found that the self-reactivity
mediated by the cooperation of memory-like CD8
+ and CD4
+ T cells was not abrogated by CD40L blockade. In contrast,
treatment with anti-IL-2 antibodies inhibited the onset of autoimmunity. IL-2 neutralization prevented the CD4-mediated
differentiation of memory-like CD8
+ T cells into pathogenic effectors in response to self-antigen cross-presentation.
Furthermore, in the absence of helper cells, induction of IL-2 signaling by an IL-2 immune complex was sufficient to
promote memory-like CD8
+ T cell self-reactivity.
Conclusions/Significance: IL-2 mediates the cooperation of memory-like CD4
+ and CD8
+ T cells in the breakdown of cross-
tolerance, resulting in effector cytotoxic T lymphocyte differentiation and the induction of autoimmune disease.
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Introduction
CD8
+ T cells play a key role in host defense against pathogens.
The diversity of their TCR repertoire assures recognition of the
vast majority of potential infectious agents. However, an important
consequence of this diversity is the risk of pathogenic anti-self
responses. Although the immune system has developed mecha-
nisms of peripheral tolerance that prevent self-reactivity, CD8
+ T
cells may become activated, under conditions not yet well
understood, resulting in autoimmunity. Many T cell-mediated
autoimmune diseases have an extremely complex etiology with
multiple genetic and environmental factors contributing to disease.
This indicates that CD8
+ T cells need to override multiple
checkpoints, including the requirements for activation signals for
antigen presenting cells (APCs) and CD4
+ T helper cells as well as
bypassing regulatory T cell (Treg) suppression and molecular
negative T cell regulators, in order to become pathogenic effectors
[1,2]. Our increasing understanding of these control mechanisms
has opened new opportunities for therapeutic interventions in
autoimmunity as well as cancer immunotherapy, since the latter is
generally limited by tolerance [3,4,5].
Lymphopeniahas beenlinkedto autoimmunityin many different
murine models and more circumstantially in patients [6,7].
Furthermore, lymphodepletion enhances anti-self-tumor antigen
responses after adoptive T cell immunotherapy [8,9]. These
observations point to lymphopenia as a factor that perturbs the
mechanisms of peripheral tolerance. At least three important
features, common to most of the models assessed thus far, may
explain how lymphopenia interferes with tolerance. First, lympho-
penia may result in an imbalance between pathogenic and Tregs,
with a preferential loss of the later. This is observed when
pathogenic T cells are transferred into severely lymphopenic hosts
and in 3-day old thymectomized mice [10,11]. Also, chemically
induced lymphopenia may induce a preferential loss of Tregs [12].
However, the loss of Tregs cannot in itself explain self-reactivity
since their absence in lymphoreplete adult animals does not result in
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absence of Tregs may result in the generalized activation of APCs
[15,16]. Third, lymphopenia induces the antigen-independent
activation of potentially autoreactive T cells. Naı ¨ve T cells
proliferate under acute lymphopenic conditions in response to the
same factors that promote their survival in lymphoreplete mice, the
cytokine IL-7 and TCR engagement with self-peptide/MHC
complexes [17,18,19,20,21,22]. This proliferation is accompanied
by a direct differentiation into memory-like T cells in the apparent
absence of antigenic stimulation [23,24,25]. Indeed, these cells are
functionally and phenotypically similar to bona-fide memory cells
[26]. However, subtle differences have recently been observed in
their homing and expansion capabilities [27]. Interestingly, It has
been shown that memory-like T cells are less prone to tolerization
than naı ¨ve cells, most likely due to their less stringent requirements
for activation [28].
We have previously shown that potentially autoreactive
memory-like CD8
+ T cells are able to induce autoimmunity
under lymphopenic conditions [29]. This was evaluated by
transfer of transgenic Clone 4 CD8
+ T cells bearing an inluenza
virus hemagglutinin (HA)-specific, H2-K
d restricted TCR into
lymphopenic mice wherein HA is expressed under the control of
the rat insulin promoter in the beta cells of the pancreas (termed
InsHA mice). However, the onset of autoimmunity was strictly
dependent on the presence of HA-specific CD4
+ T helper cells
from HNT transgenic mice [29]. Similar results were obtained in
the RIP-GP mouse model, where in vitro activated CD4
+ T helper
cells promoted the autoimmune attack of GP-specific endogenous
CD8
+ T cells under lymphopenic conditions [30]. Interestingly, in
our model, help could be provided by memory-like CD4
+ T cells
generated in vivo upon lymphopenia-induced proliferation. These
helper cells promoted the further differentiation of memory-like
CD8
+ T cells into cytotoxic T lymphocytes (CTL) in response to
antigen cross-presentation and their migration to the site of
antigen-expression [29]. In the absence of help, however, memory-
like CD8
+ T cells were tolerized in the draining lymph nodes (LN)
of the pancreas [29]. Importantly, the cotransfer of naı ¨ve HA-
specific CD8
+ and CD4
+ T cells into lymphoreplete InsHA mice
did not result in autoimmunity and CD8
+ T cells were tolerized
under these conditions [29,31]. Thus, overcoming cross-tolerance
requires the cooperation of memory-like CD8
+ and CD4
+ T cells.
Many studies have assessed the helper dependent generation of
primary CTL responses [32]. It is generally accepted that CD4
+
help is required under non-inflammatory conditions where
dendritic cells are not sufficiently activated by pathogen associated
molecular patterns [32]. Under these conditions, CD4
+ T helper
cells would be required to activate antigen presenting dendritic
cells, through the engagement of CD40, that in turn would
efficiently activate naı ¨ve CD8
+ T cells by expressing co-stimulatory
receptors and cytokines [33,34,35]. However, there is a dearth of
information on the molecular pathways involved in the cooper-
ation between memory-like CD4
+ and CD8
+ T cells. In this study,
we address the molecular basis of this cooperation. We found a
major role for the IL-2 cytokine in the helper-dependent
differentiation of memory-like Clone 4 CD8
+ T cells into effectors
capable of inducing autoimmunity and overcome cross-tolerance
in lymphopenic InsHA mice.
Results
CD40L blockade does not prevent the induction of
autoimmune diabetes by memory-like T cells
As we previously reported [29], cotransfer of naı ¨ve HA-specific
Clone 4 CD8
+ T cells together with HNT CD4
+ Tc e l l si n t o
sublethaly irradiated InsHA mice promoted the onset of
autoimmune diabetes in the vast majority of animals between
days 9 and 13 (Table 1). In this model, lymphopenia induced the
proliferation and differentiation of both potentially autoreactive
CD8
+ as well as CD4
+ T cells into memory-like cells. Upon
antigen encounter, cross-presented in the draining lymph nodes of
the pancreas, the further differentiation of memory-like CD8
+ T
cells into effector CTL that migrated to the pancreas and
mediated beta cell destruction was dependent on antigen-specific
memory-like CD4
+ T cell help [29]. To determine the molecular
basis of this cooperation, we first targeted the CD40L/CD40
pathway, thought to be the main pathway involved in the
provision of CD4
+ help [32], by using the anti-CD40L blocking
monoclonal antibody (mAb) MR1 [36]. This well characterized
mAb has been extensively used to block CD40 engagement by
CD40L expressing cells. Lymphopenic InsHA mice, coinjected
with equal numbers of Clone 4 CD8
+ and HNT CD4
+ Tc e l l s ,
were treated every other day with 0,5 mg of the MR1 mAb.
Surprisingly, the vast majority of treated mice still developed
autoimmune diabetes (11/12), although the onset was slightly
delayed (day 1362 as compared to day 1061 in control mice that
received an isotype control mAb).
Analyses of the CFSE profiles of donor CD8
+ T cells showed
extensive proliferation in draining and non draining LN for both
groups, although the proliferation rate was slightly delayed in the
pancreatic (p)LN of anti-CD40 treated mice (Fig. 1A). However,
neither absolute numbers of recovered Clone 4 CD8
+ T cells nor
migration of donor CD8
+ T cells to the pancreas differed
significantly in anti-CD40 as compared to isotype treated mice
(Fig. 1C and D).
Since the MR1 mAb targets the interaction between CD4
+ T
cells and APCs, we next analyzed its effect on transferred HNT
CD4
+ T cells. Donor CD4
+ T cells in control mice showed a
bimodal proliferation profile, with most cells having undergone
Table 1. IL-2 mediates CD4 help for memory-like Clone 4 CD8
+ T cells in the induction of autoimmune diabetes.
Cell Transfer
a Treatment
b Diabetes incidence
c
Clone 4 CD8
++ HNT CD4
+ 5610
6+5610
6 + isotype control 100% (n=13) d 1061
+ a-CD40L(MR-1) 92% (n=12) d 1362
Clone 4 CD8
++ HNT CD4
+ 5610
6+5610
6 + isotype control 85% (n=13) d 1161
+ a-IL-2(S4B6+JES6-1) 38% (n=16) d 1562
aPurified transgenic CD8
+ and CD4
+ T cells were injected as indicated into irradiated InsHA mice, 24 h after irradiation.
bMice were treated either with MR1 anti-CD40L mAb or S4B6+JES6-1 anti-IL-2 mAbs or with their respective isotype matched antibodies.
cThe onset of autoimmunity was evaluated by measuring blood glucose levels. Mice were followed over a 21 day period and were considered diabetic when levels were
above 300 mg/dl in two consecutive measurements. The day of disease onset (d) is indicated.
doi:10.1371/journal.pone.0012659.t001
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five or more rounds (Fig. 1B). This behavior has previously been
observed for adoptively transferred polyclonal CD4
+ Tc e l l si n t o
irradiated mice [37]. Interestingly, anti-CD40L treatment
almost completely reduced the presence of highly proliferating
CD4
+ T cells in draining but, also, in non-draining LN (Fig. 1B).
Although absolute numbers of recovered CD4
+ Tc e l l sf r o mt h e
LN were not significantly different, we found a highly significant
three-fold reduction in the CD4
+ T cells that migrated to the
pancreas of InsHA mice (Fig. 1D). This was not surprising
because only highly proliferating CD62L
lo T cells were detected
in the pancreas of non-treated mice (data not shown). To
determine whether the blocking effect of MR1 on HNT CD4
+ T
cell proliferation was driven by lymphopenia and/or the HA
antigen, we performed adoptive transfer experiments in
l y m p h o p e n i cM R 1t r e a t e dB A L B / cm i c e .I nt h i sH Aa n t i g e n -
independent environment, anti-CD40L again reduced the
numbers of highly proliferating CD4
+ T cells (Fig. 2A), whereas
proliferation profiles of donor CD8
+ Tc e l l sw e r en o t
significantly different (Fig. 2B). Taken together, our results
show that CD40L blockade has an unsuspected effect on the
lymphopenia-induced proliferation of donor CD4
+ T cells but
does not prevent their ability to promote the CD8
+ T cell-
mediated onset of disease.
IL-2 neutralization prevents autoimmune diabetes
induced by the cooperation of memory-like CD4
+ and
CD8
+ T cells
We next targeted IL-2, a cytokine mainly produced by CD4
+ T
cells, whose role in help for CD8
+ T cell responses remains
controversial [32,38]. To assess the effect of inhibiting a potential
IL-2 mediated response in the onset of disease in InsHA mice, we
utilized a combination of two neutralizing mAbs, S4B6 and JES6-
1 recognizing different epitopes on the IL-2 molecule [39]. Large
amounts of S4B6 have been shown to neutralize circulating IL-2 in
vivo inducing a decrease in Tregs, which are dependent on IL-2
for their homeostasis ([40] and Fig. S1). However, this mAb can
potentially form an immune complex with IL-2 and induce CD8
+
T cell proliferation [39]. Thus, we used S4B6 in combination with
JES6-1 because it has been shown that the later can block the
effect of IL-2/S4B6 complexes in vitro [39]. Lymphopenic InsHA
mice injected with Clone 4 CD8
+ and HNT CD4
+ T cells were
treated with 0.5 mg of a 1:1 combination of S4B6 and JES6-1
every other day. Notably, anti-IL-2 treatment prevented the onset
of autoimmune diabetes in 62% of treated mice (10/16), whereas
most of the mice in the isotype control mAb treated group (10/11)
developed disease (Table 1). Furthermore, all but one of the anti-
IL-2 treated mice that showed hyperglycemia developed a milder
form of disease remaining alive until the end of the experiment.
Figure 1. Analysis of proliferating donor T cells in anti-CD40L treated InsHA mice. Irradiated InsHA mice were injected with either CFSE-
labeled naı ¨ve Clone 4 Thy1.1
+ CD8
+ T cells or with a combination of CFSE-labeled Clone 4 Thy1.1
+ CD8
+ T cells and CFSE-labeled HNT Thy1.1
+ CD4
+ T
cells. Mice were treated with either an anti-CD40L mAb (MR1) or an isotype matched control antibody and the presence of donor T cells in different
organs was analyzed on day 13 after transfer. Data from one representative experiment out of four, including an average of 3 mice per group, are
presented. Levels of CFSE fluorescence on gated CD8
+ (A) or CD8
2 (B) Thy1.1
+ donor lymphocytes in LN and pLN are shown. The mean percentages
(6 SD, n=3) of highly proliferating ($5 rounds of division) CD8
+ or CD4
+ donor T cells, respectively, are indicated. (C) Absolute numbers of donor T
cells in the lymphoid organs were enumerated following treatment with with MR1 anti-CD40L mAb (black bars) and isotype control antibody (empty
bars). Results are presented as means 6 SD (n=4). (D) The presence of CD8
+ Thy1.1
+ and CD8
2 Thy1.1
+ donor T cells in the pancreas was evaluated
by FACS. Numbers indicate FACS event counts in the depicted gates. Graphs represent mean (6 SD, n=3) recovered CD8
+ or CD4
+ donor T cells in
groups of mice described in panel C.
doi:10.1371/journal.pone.0012659.g001
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very rapidly, becoming moribund within three days following the
onset of hyperglycemia.
In agreement with these results, we found that IL-2 neutrali-
zation blocked the migration of donor CD8
+ T cells into the
pancreas in 50% of mice analyzed at day 13 post transfer and
reduced the number of infiltrating cells in the remaining mice
(Fig. 3C). We found no significant differences in the proliferation
profiles of donor CD8
+ T and CD4
+ T cells from treated and non-
treated animals in either draining or non-draining lymph nodes
where proliferation was extensive (Fig. 3A and data not shown).
Surprisingly, anti-IL-2 treatment enhanced the accumulation of
Clone 4 CD8
+ T cell in the lymphoid tissue (Fig. 3B). Collectively,
our data suggest that IL-2 plays a major role in the induction of
autoimmune diabetes by memory-like Clone 4 CD8
+ T cells.
IL-2 neutralization blocks the CD4-mediated
differentiation of memory-like CD8
+ T cells into effectors
in response to self-antigen cross-presentation
In the experiments described above, most of the CD8
+ T cell
proliferation observed in lymphoid organs was driven by the state
of lymphopenia itself masking the potential proliferation induced
by the cross-presentation of low amounts of the HA self-antigen in
the pLN. It is precisely in this location where CD4
+ T helpers
exert their effects by enhancing the proliferation of memory-like
CD8
+ T cells in response to antigen cross-presentation and
promoting their differentiation into effectors [29]. To specifically
investigate this process, we performed double transfer experiments
in which homeostatic proliferation/differentiation was uncoupled
from antigen recognition. InsHA mice were irradiated and
injected with naı ¨ve HNT CD4
+ T cells. After 12 days, all mice
were injected with lymphocytes from naı ¨ve non-irradiated InsHA
mice in order to ‘‘fill’’ the space and prevent any subsequent
lymphopenia-induced proliferation. After resting for an additional
4 days, InsHA mice received CFSE labeled memory-like Clone 4
CD8
+ T cells that had been generated by their prior transfer into
irradiated BALB/c mice. At the time of secondary transfer, Clone
4 cells isolated from irradiated BALB/c mice were CD44
hi CD25
2
CD62L
hi, a typical central memory phenotype. Five days later,
InsHA mice were sacrificed and proliferation of donor Clone 4
cells was assessed in the lymphoid organs.
As we have previously shown, HNT CD4
+ T cells dramatically
enhanced the proliferation of memory-like Clone 4 CD8
+ T cells
in response to self-antigen cross-presentation in the pLN and,
more importantly, it was only in their presence that the Clone 4
CD8
+ T cells migrated to the pancreas ([29] and Fig. 4A).
Treatment with anti-CD40L did not significantly modify the
proliferation profiles of Clone 4 CD8
+ T cells (Fig. 4A). In marked
contrast, IL-2 neutralization prevented the enhanced proliferation
induced by CD4 help in the pLN of InsHA mice (Fig. 4A).
Notably, IL-2 neutralization blocked the migration of CD8
+ T
cells to the pancreas in all animals tested, whereas anti-CD40L
only had a moderate effect (Fig. 4A and B).
Finally, we assessed the phenotype of proliferating Clone 4
CD8+ T cells in the pLN. As previously described, CD4 help
induced the differentiation of highly proliferating memory-like
CD8
+ T cells into effectors as demonstrated by the dowregulation
of CD62L and the upregulation of CD25 in control mice (Fig. 4C)
[29]. IL-2 neutralization also blocked this differentiation (Fig. 4C),
whereas anti-CD40L did not (data not shown). It is important to
note that while anti-IL-2 treatment prevented antigen driven
proliferation and differentiation in the pLN, it also induced a non-
specific proliferation of memory-like CD8
+ T cells in non-draining
LN (Fig. 4A). Proliferating cells retained a central memory
phenotype (Fig. 4C). This may reflect the formation of an immune
complex between S4B6 mAb and endogenous IL-2 [39] and the
inability of JES6-1 mAb to completely prevent their immunosti-
mulatory effects on memory-like CD8
+ T cells in vivo and would
explain the enhanced accumulation of Clone 4 cells in the LN of
long term anti-IL-2 treated mice that did not develop diabetes (see
Fig. 3B).
IL-2 signaling promotes memory-like CD8
+ T cell
mediated autoimmune diabetes in the absence of CD4
+
help
To determine whether the induction of an IL-2 signaling
cascade in CD8
+ T cells was sufficient to account for the effects of
CD4 help in the onset of autoimmune diabetes in InsHA mice, we
sought to substitute HNT CD4
+ T cells by an exogenous source of
IL-2. However, daily treatment of lymphopenic InsHA mice for 5
consecutive days with recombinant IL-2 did not result in the onset
of disease following transfer of Clone 4 CD8
+ T cells (data not
shown). We hypothesized that the absence of an IL-2 mediated
effect might have been due to its extremely short half-life in vivo.I t
has recently been shown that the in vitro formation of IL-2/anti-IL-
2 mAb immune complex prior to injection can augment the half-
life and functionality of IL-2 [39,41,42]. Therefore, we next
utilized IL-2/S4B6 (2 mg/10 mg) immune complex as an exoge-
nous source of IL-2. Notably, 100% of the IL-2/S4B6 treated
InsHA mice developed autoimmune diabetes following adoptive
transfer of Clone 4 CD8
+ T cells alone (Table 2). This was
associated with a dramatically enhanced proliferation of Clone 4
CD8
+ T cells in the pLN as well as in non draining LN (Fig. 5A
and C). This is in agreement with previous observations showing
that this immune complex induces antigen-independent expansion
of memory phenotype CD8
+ T cells [39]. Most importantly, IL-2
complexes promoted the differentiation of memory-like Clone 4
CD8
+ T cells into effectors capable of migrating to the pancreas,
only in the pLN (Fig. 5B). In marked contrast, control mice treated
Figure 2. Anti-CD40L treatment inhibits rapid lymphopenia-
induced CD4
+ T cell proliferation. Irradiated BALB/c mice were
injected with CFSE-labeled naı ¨ve Clone 4 Thy1.1
+ CD8
+ T cells and CFSE-
labeled HNT Thy1.1
+ CD4
+ T cells. Mice were treated with either an anti-
CD40L mAb (MR1) or an isotype matched antibody and the presence of
donor T cells in LN was analyzed on day 13 after transfer. Levels of CFSE
fluorescence on gated Thy1.1
+ donor lymphocytes were analyzed. The
mean percentages (6 SD, n=3) of highly proliferating CD4
+ (A) and
CD8
+ (B) donor T cells are indicated.
doi:10.1371/journal.pone.0012659.g002
IL-2 Mediates CD4 Help
PLoS ONE | www.plosone.org 4 September 2010 | Volume 5 | Issue 9 | e12659with this low dose of S4B6 mAb alone did not develop
hyperglycemia and remained healthy over the course of the
experiments (Table 2). Thus, IL-2 in the form of an immune
complex can efficiently substitute for CD4 help, promoting the
differentiation of CTL capable of overcoming self-tolerance and
inducing autoimmunity under lymphopenic conditions.
Discussion
In this report, we examined the mechanisms via which memory-
like CD8
+ and CD4
+ T cells cooperate to overcome cross-
tolerance and induce self-reactivity under lymphopenic conditions.
Our findings demonstrate a key role for IL-2 in the CD4-mediated
differentiation of memory-like CD8
+ T cells into diabetogenic
effectors. We showed that IL-2 neutralization prevents the
differentiation of the CD8
+ T cells in response to self-antigen
cross-presentation in the pLN and their subsequent migration to
the pancreas. Furthermore, in the absence of helper cells, IL-2
signaling is sufficient to transform a tolerogenic antigenic stimulus
for memory-like CD8
+ T cells into a priming stimulus [43].
IL-2 has long been known for its adjuvant effects on CD8
+ T
cell expansion. For this reason, it was proposed as the factor that
CD4
+ T helper cells provide for CD8
+ T cell responses [44].
However, the finding that IL-2 deficient mice are able to mount
primary CD8
+ T cell responses and that CD4
+ T cells condition
DC, through CD40L/CD40 interactions, to efficiently prime
CD8
+ T cells disfavored the original hypothesis [33,34,35,45].
Recently though, it has been shown that IL-2 is required for the
generation of functional anti-pathogen memory CD8
+ T cells
[46,47]; IL-2 appears to be needed at the time of priming and can
Figure 3. Anti-IL-2 treatment inhibits migration of Clone 4 CD8
+ T cells to the pancreas of InsHA mice. Irradiated InsHA injected with
CFSE-labeled naive Clone 4 Thy1.1
+ CD8
+ T cells plus HNT Thy1.1
+ CD4
+ T cells were treated with either a combination of anti-IL-2 mAbs (S4B6+ JES6-
1) or an isotype matched control antibody. Mice were sacrificed on day 12 after transfer and the presence of donor T cells in different organs was
analyzed. Data from one representative experiment out of four, including an average of 3 mice per group, are presented. (A) Levels of CFSE
fluorescence on gated CD8
+ Thy1.1
+ donor lymphocytes in LN and pLN are shown. The mean percentages (6 SD, n=3) of highly proliferating CD8
+
donor T cells are indicated. (B) Absolute numbers of CD8
+ donor T cells in the lymphoid organs were enumerated following the treatment with anti-
IL-2 mAbs (S4B6+ JES6-1) (black bars) and an isotype matched control antibody (empty bars). Results are presented as means 6 SD (n=3). (C) The
presence of CD8
+ Thy1.1
+ donor T cells in the pancreas was evaluated by FACS. Numbers indicate FACS event counts in the depicted gates. Graphs
represent mean (6 SD, n=3) recovered CD8
+ donor T cells in control mice (empty bars), anti-IL-2 treated mice containing .10
3 donor cells (black
bars) and anti-IL-2 treated mice containing ,10
3 donor cells (grey bars).
doi:10.1371/journal.pone.0012659.g003
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+ T cells into effectors in response to self-
antigen cross-presentation. Irradiated InsHA mice were either injected with 5610
6 CFSE-labeled naı ¨ve HNT Thy1.1
+ CD4
+ T cells or PBS. On day
12, both groups of mice were ‘‘refilled’’ with 100610
6 spleen and LN cells from unmanipulated InsHA mice. Four days later, the ‘‘refilled’’ InsHA mice
received enriched CFSE-labeled memory-like Clone 4 Thy1.1
+ CD8
+ T cells, generated by injection of naı ¨ve cells into irradiated BALB/c mice 16 days
previously. Mice adoptively transferred with HNT CD4
+ T cells were also treated with either anti-CD40L, anti-IL-2 or the respective isotype matched
control antibodies. Five days after secondary transfer, InsHA mice were sacrificed and donor CD8
+ Thy1.1
+ lymphocytes from pancreas, LN and pLN
were analyzed by FACS. Data from one representative experiment of four are presented. (A) Histograms represent CFSE fluorescence on gated CD8
+
Thy1.1
+ lymphocytes. The presence of CD8
+ Thy1.1
+ donor T cells in the pancreas was evaluated by FACS. FACS event counts in the depicted gates
are indicated. (B) Graphs represent mean (6 SD, n=3–8 per group) recovered CD8
+ donor T cells from the pancreas of mice from indicated groups.
(C) Expression of CD25, CD62L and CD44 on gated CD8
+ Thy1.1
+ lymphocytes of mice treated with anti-IL-2 mAbs was assessed by flow cytometry.
Plots represent expression of CD25, CD62L and CD44 as a function of CFSE fluorescence on gated CD8
+ Thy1.1
+ lymphocytes in the pLN.
doi:10.1371/journal.pone.0012659.g004
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+ T helper cells [47,48]. Thus,
continued IL-2 signaling in CD8
+ T cells promotes their
differentiation into short-lived effectors [49,50,51]. Nonetheless,
in certain studies, IL-2 was not essential for the differentiation of
CD8
+ T cells into effectors during the primary response [46,47].
IL-2 may be dispensable in this latter context where CD8
+ T cells
would benefit from inflammatory signals during an infection with
the secretion of other factors with partly overlapping functions,
such as type I interferons and IL-12 [52,53,54] [51]. In our model,
where antigen encounter is likely to occur in the absence of overt
inflammation (in the absence of help, Clone 4 cells are still
tolerized in irradiated mice and do not differentiate into effectors
[29]), IL-2 appears to be the major factor driving help-dependent
Table 2. IL-2 immune complex promote memory-like Clone 4
CD8
+ T cell-mediated autoimmune diabetes in the absence of
CD4 help.
Cell Transfer
a Treatment
b Diabetes incidence
c
Clone 4 CD8
+ 5610
6 + a-IL-2(S4B6) 0% (n=7)
+ rIL-2/a-IL-2(S4B6) I.C. 100% (n=9) d 1161
aPurified transgenic CD8
+ T cells were injected as indicated into InsHA mice
24 h after irradiation.
bMice were treated with IL-2/S4B6 immune complex (I.C.) or S4B6 alone.
cMonitoring of lymphopenic InsHA mice was performed as described in Table 1.
doi:10.1371/journal.pone.0012659.t002
Figure 5. IL-2 immune complex induces the differentiation of memory-like Clone 4 CD8
+ T cells into effectors and their migration to
the pancreas. Irradiated InsHA mice injected with 5610
6 CFSE-labeled naı ¨ve Clone 4 Thy1.1
+ CD8
+ T cells were treated with IL-2/S4B6 anti-IL-2
immune complex (I.C.) or anti-IL-2. Mice were sacrificed on day 11 after transfer. Data from one representative experiment of three are presented. (A)
Levels of CFSE fluorescence on gated CD8
+ Thy1.1
+ donor lymphocytes in LN and pLN are shown. The mean percentages (6 SD, n=3) of proliferating
CD8
+ donor T cells are indicated. The presence of CD8
+ Thy1.1
+ donor T cells in the pancreas was evaluated by FACS. FACS event counts in the
depicted gates are indicated. (B) Plots represent expression of CD25 and CD44 as a function of CFSE fluorescence on gated CD8
+ Thy1.1
+ lymphocytes
in the pLN. (C) Absolute numbers of CD8
+ donor T cells in the lymphoid organs were enumerated following treatment with with IL-2/S4B6 I.C. (black
bars) and S4B6 mAb (empty bars). Results are presented as means 6 SD (n=3).
doi:10.1371/journal.pone.0012659.g005
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+ T cells into effectors in
response to self-antigen cross-presentation.
Our results show that there is no major role for the CD40L
pathway in help provided by self-antigen specific HNT CD4
+ T
cells in lymphopenic InsHA mice. Previous reports have shown
that CD4 help could be fully or partially independent of the
CD40L/CD40 pathway [31,55,56], but our finding was somewhat
surprising in light of a recent study showing that CD8
+ T cells
proliferating under lymphopenic conditions required CD4 help to
induce autoimmunity and that this help was mediated by CD40
engagement on APCs [30]. However, in this previous study, help
was provided by CD4
+ T cells activated in vitro with antigen
whereas, in the experiments reported here help was provided by
memory-like CD4
+ T cells generated in vivo upon lymphopenia
induced proliferation. Memory phenotype CD4
+ T cells and
effector cells express very different levels of CD40L ([48,57] and
data not shown). It is interesting to speculate that the
differentiation state of the CD4
+ T helper cells could regulate
the pathway utilized to provide help. Furthermore, it has been
shown that irradiation promotes the upregulation of co-stimula-
tory molecules on dendritic cells by mean of the release of TLR
ligands [15]. Since lymphopenia is induced by irradiation in our
model, activation of the cross-presenting APCs could by-pass the
need for CD40 engagement by CD4
+ T helpers.
Notably, we found an unsuspected role for CD40L in the
lymphopenia-induced proliferation of CD4
+ T cells. This is in
apparent contradiction with a previous study showing that CD40L co-
stimulation did not play a role in lymphopenia-induced proliferation
of CD4
+ T cells in irradiated hosts [58]. However, in this report only
cells undergoing one or two rounds of division, the classical
homeostatic proliferation, were analyzed [58]. Our results demon-
strate that the proliferation of a small proportion of cells undergoing
many rounds of division in irradiated hosts is CD40L dependent.
The data presented here clearly manifest the dual role of IL-2 in
maintaining self-tolerance and promoting CD8
+ T cell immunity.
Our results are consistent with recent reports showing that IL-2
not only promotes proliferation and survival of CD8
+ T cells but
also their differentiation into effectors [43,59,60]. Thus, IL-2
allows Clone 4 CD8
+ T cells to overcome cross-tolerance and
initiate an autoimmune response. On the other hand, Tregs are
dependent on IL-2 for their growth and survival and can be
eliminated by the use of neutralizing anti-IL-2 mAbs [40,61,62].
In our model, autoimmunity ensues while mice are lymphopenic
and there is a likely imbalance between effector cells and Tregs
[29]. The use of neutralizing anti-IL-2 mAbs in InsHA mice not
only prevents the help mediated differentiation of memory-like
CD8
+ T cells but, at the same time, it further decreases the
number of Tregs. One possibility as to why IL-2 neutralization was
not 100% effective in preventing disease (reaching 62%, see
Table 1) could be due to the additional depletion of Tregs. This
observation illustrates the key role of IL-2 in regulating the fine
equilibrium between CD8
+ T cell tolerance and immunity [63,64].
Our results, showing that IL-2 immune complex can promote the
breakdown of peripheral tolerance by memory-like CD8
+ T cells
in the absence of CD4
+ T cells help, have important implications
for the development of therapies for autoimmune diseases as well
as cancer immunotherapies.
Materials and Methods
Ethics statement
All experimental procedures were approved by the ‘‘Direction
De ´partamentale des Services Ve ´terinaires’’, authorization number
D-34-172-16 and 34.347. Blood withdrawal from the retro orbital
sinus was performed under isoflurane anesthesia. Diabetic mice
were sacrificed to prevent suffering by prolonged hyperglycemia.
Mice
BALB/c mice were purchased from Charles River and then
housed at the Institut de Ge ´ne ´tique Mole ´culaire de Montpellier
(IGMM). InsHA [65], Clone 4 TCR [66] and HNT TCR [67]
(kindly provided by Linda A. Sherman, The Scripps Research
Institute) transgenic mice lines were backcrossed with BALB/c
mice for at least 10 generations. Clone 4 and HNT mice were then
crossed with BALB/c Thy1.1
+/+ for two generations to achieve
homozygosity for Thy1.1. All mice used in these studies were
between 8 and 16 weeks of age. Mice were propagated and
maintained under specific pathogen-free conditions in the IGMM
animal facility.
Preparation of CFSE labeled naı ¨ve TCR transgenic T cells
CD8
+ T cells from Clone 4 TCR Thy1.1 transgenic mice and
CD4
+ T cells from HNT Thy1.1 were prepared from single cell
LN suspensions by magnetic depletion using the T cell isolation
kits and an AutoMACS apparatus from Miltenyi according to the
manufacturer’s instructions. T cell purity was greater than 90%.
Purified T cells (2610
7 cells/ml) were labeled with 5 mM 5- and 6-
carboxy-fluorescein succinimidyl ester (CFSE) (Molecular Probes,
Eugene, OR) in PBS for 10 min at 37uC.
Induction of lymphopenia by irradiation
BALB/c or InsHA mice were sublethaly irradiated (450 rads)
utilizing a therapeutic irradiator, Variant. Under these conditions,
depletion of host T cells was approximately 90% at 24 h after
irradiation and 70% at 7 days. Mice were used for adoptive
transfer experiments 24 h after irradiation, unless otherwise noted.
Adoptive transfer
4–5610
6 CFSE-labeled Clone 4 TCR Thy1.1 CD8
+ T cells
and/or 4–5610
6 CFSE-labeled HNT TCR Thy1.1 CD4
+ T cells
in PBS were transferred by i.v. injection into irradiated InsHA and
BALB/c mice.
For double transfer experiments, InsHA mice were irradiated
and 24 h later, they either received HNT TCR Thy1.1 CD4
+ T
cells or PBS. All mice were ‘‘refilled’’ with a mixture of 100610
6
spleen and lymph node cells from non-irradiated InsHA mice 12
days later. At day 16, the InsHA mice received secondary i.v.
transfers of CFSE-labeled, enriched memory-like Clone 4 TCR
Thy1.1 CD8
+ T cells. These latter cells were obtained from the
lymph nodes and spleen of irradiated BALB/c mice that had been
injected 16 days earlier with naive Clone 4 TCR Thy1.1 CD8
+ T
cells. Cells recovered from one single primary host were
transferred into one secondary recipient mouse.
In vivo treatments with antibodies and cytokines
Purified anti-CD40L (clone MR1, Hamster IgG (BioXcell):
0.5 mg/mouse suspended in PBS) was administered by i.p.
injection every other day starting on day 1 after transfer until
mice were hyperglycemic. In double transfer experiments, mice
were treated from day 11 before CD8
+ T cell transfer until the end
of the experiment. Anti-IL-2 (Clones S4B6 and JES6-1, Rat
IgG2a, (BioXcell): 0.25 mg of each mAb/mouse) was adminis-
tered by i.p. injection every other day starting on day 1 after
transfer. In double transfer experiments, mice were treated from
the day of CD8
+ T cell transfer until the end of the experiment.
Recombinant mIL-2 was purchased from Peprotech. IL-2
immune complex, preformed in vitro by mixing 2 mgo f
IL-2 Mediates CD4 Help
PLoS ONE | www.plosone.org 8 September 2010 | Volume 5 | Issue 9 | e12659recombinant mIL-2 and 10 mg of the S4B6 anti-IL-2 mAb in PBS,
was administered by i.p. injection. Mice were treated on five
consecutive days starting at day 5 after transfer.
Diabetes monitoring
Mice were monitored for diabetes by measuring blood glucose
every 4 days for a maximum period of 21 days with a GlucomaticH
ESPRIT Apparatus (Bayer, France). In some instances, daily
measurements were performed on urine samples with MultistixH 8
SG strips (Bayer, France). Animals were considered diabetic when
glucose levels were above 300 mg/dl during two consecutive
measurements.
Flow cytometry
Pancreas, pancreatic (pLN) and a mixture of inguinal, axillary,
cervical, mandibular, popliteal and mesenteric LN were excised
and processed separately to obtain single cell suspensions by
mechanical disruption on Nitex filters in PBS containing 5% FCS
at 4uC. After counting, all pancreatic LN cells and an equivalent
number of cells from other LN and spleen were stained with the
indicated Abs. For the pancreas, suspensions were subject to
Histopaque separation and all cells obtained from a single
pancreas were stained.
All mAbs and secondary reagents were purchased from BD
PharMingen (San Diego CA) except anti-CD44-APC-Alexa
FluorH 750 and anti-Foxp3-APC mAbs (eBioscience, San Diego,
CA). Donor Clone 4 and HNT T cells were detected and
enumerated by virtue of Thy1.1 expression. Lymphocytes were
incubated with anti-CD8a-PerCP and anti-Thy1.1-PE mAbs in
PBS containing 2% FCS and 0.02% sodium azide for 30 min at
4uC. After washing, cells were analyzed on a FACSCanto II
apparatus using Diva software (BDB, Mountain View, CA).
For Clone 4 CD8
+ T cells, the intensity of CFSE fluorescence
was analyzed in the CD8
+ Thy1.1
+ subpopulation of lymphocytes.
For HNT cells, this was performed by gating on CD8
2 Thy1.1
+ or
CD4
+ Thy1.1
+ T cells depending on the experiment. To assess the
phenotype of proliferating T cells, they were stained with anti-
CD25-PE-Cy7, anti-CD62L-APC and anti-CD44-APC-Alexa
FluorH 750 mAbs. Intracellular Foxp3 staining was performed
utilizing the Fixation and Permeabilization Kit (eBioscience)
according to manufacturer’s instructions.
Statistical analyses
Statistical significance was determined using a Student’s t test
with a one-tailed distribution and two-sample equal variance. Data
were considered to be statistically different (*) for P ,0.05.
Supporting Information
Figure S1 IL-2 neutralization depletes Tregs in lymphopenic
InsHA mice. Mice described in Figure 3 were sacrificed at day 13
after transfer and expression of CD25, and Foxp3 was assessed on
gated endogenous CD4
+ Thy1.1
2 T cells in LN. The mean
percentages (6 SD, n=3) of CD4
+ CD25
+ FoxP3
+ T cells are
indicated. Data from one representative experiment out of four,
including an average of three mice per group, are presented. A
30% reduction in the frequency of Tregs was observed in InsHA
mice treated with anti-IL-2 mAbs as compared to isotype control
treated mice.
Found at: doi:10.1371/journal.pone.0012659.s001 (0.70 MB EPS)
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